Li Qiang, secretary of the Jiangsu Provincial CPC Committee, met Tuesday in Nanjing with Pascal Soriot, Executive Director and Chief Executive Officer of the Anglo-Swedish pharmaceutical firm AstraZeneca.
Li Qiang briefed Pascal Soriot on the province’s economic and social situations, adding that Jiangsu has a solid foundation in its manufacturing industry against the backdrop of a high level of openness to the outside world and a rich assortment of scientific and technological talents.
The CPC chief noted that Jiangsu enjoys good foundations and conditions for the development of the pharmaceutical industry, adding that the province has prioritized biomedicine as one of the province's strategic emerging industries.
As the global pharmaceutical leader, AstraZeneca has achieved good return on investment with is investment projects in Jiangsu, said Li Qiang.
Li pledged that the provincial authorities will as always give firm support to the AstraZeneca projects in Taizhou and Wuxi through the enhanced protection of intellectual property rights and the boost of top quality services.
He also hoped that both sides would promote the pragmatic cooperation in terms of biomedicine and the Internet of medical things for mutually complimentary gains.
Mr Soriot said AstraZeneca feels optimistic about its development in Jiangsu, adding that AstraZeneca will bring into full play its advantages to deepen its cooperation with Jiangsu in medical R&D and the Internet of medical things for more fruitful cooperative results.
